We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03567447
Recruitment Status : Unknown
Verified October 2019 by St. Joseph's Hospital and Medical Center, Phoenix.
Recruitment status was:  Recruiting
First Posted : June 25, 2018
Last Update Posted : October 29, 2019
Sponsor:
Collaborators:
H. Lundbeck A/S
Arizona State University
Information provided by (Responsible Party):
St. Joseph's Hospital and Medical Center, Phoenix

Brief Summary:
This will be a Phase II single center, double-blind, randomized, placebo-controlled, efficacy study. Subjects will complete six visits. The first will be a screening visit. There will be four assessment visits: baseline, 2 weeks after the double-blinded trial begins, the end of the blinded trial, and after 4 weeks of washout. There will also be an additional randomization and medication dispensing visit immediately following the dose optimization period and preceding the double-blinded trial.

Condition or disease Intervention/treatment Phase
Parkinson Disease Falls Patient Drug: Droxidopa Other: Placebo Phase 2

Detailed Description:

Injuries associated with falls continue to pose a significant burden to patients with Parkinson's disease (PD) both in terms of human suffering and economic losses. Overall annual fall incidence rates range from 50-70% for PD patients, and recurrent falls are a major cause of disability in PD. Approximately 20% of patients with Parkinson's disease develop NOH which can lead to falls. Although the mechanisms underlying impaired postural stability and falls are not well-known in patients with PD, attention is focused on the noradrenergic system. L-DOPS, a drug that enhances norepinephrine levels in peripheral and central nervous system, has been shown to moderate NOH, and often improve symptoms concomitant of PD and falls.

This study will help to determine the effect of L-DOPS in reducing falls and fall severity by using an instrumented walkway to induce slip perturbations can assess the propensity for falls and fall-related outcomes. It will assess fall events from the point of initiation through recovery. The effect of L-DOPS on gait and balance parameters will also be measured using force plate and inertial measurement unit (IMU) testing, and improvement in clinical scores such as the MDS-UPDRS will be monitored.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Phase II single center, double-blind, randomized, placebo-controlled, efficacy study
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Masking Description: Double blind masking
Primary Purpose: Treatment
Official Title: Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH)
Actual Study Start Date : August 17, 2018
Estimated Primary Completion Date : December 1, 2019
Estimated Study Completion Date : March 1, 2020


Arm Intervention/treatment
Experimental: Treatment group
This group will receive droxidopa 100mg to 600mg three times a day (TID) titration for 2 weeks and then maintenance dosage for 4 additional weeks. We will assess participants two times over the 4-week intervention. Each assessment will be the same as the baseline assessment, including the Orthostatic Hypotension Symptom Assessment (OHSA), postural, and gait assessments, and will be administered during the 2nd and 4th weeks following onset of stable treatment phase.
Drug: Droxidopa
starting with 100 mg TID and increasing in 100 mg TID increments, to a maximum of 600mg TID, to identify the highest tolerated dose for each patient.
Other Name: NORTHERA

Other: Placebo
appearing to be 100 mg TID and increasing in 100 mg TID increments, to a maximum of 600mg TID, to identify the highest tolerated dose for each patient.

Placebo Comparator: Non treatment group
This group will receive placebo appearing to be 100mg to 600mg three times a day (TID) titration for 2 weeks and then maintenance dosage for 4 additional weeks. We will assess participants two times over the 4-week intervention. Each assessment will be the same as the baseline assessment, including the Orthostatic Hypotension Symptom Assessment (OHSA), postural, and gait assessments, and will be administered during the 2nd and 4th weeks following onset of stable treatment phase.
Other: Placebo
appearing to be 100 mg TID and increasing in 100 mg TID increments, to a maximum of 600mg TID, to identify the highest tolerated dose for each patient.




Primary Outcome Measures :
  1. Change in number of falls [ Time Frame: Study weeks 2, 4 and 8 ]
    The effect of L-DOPS on falls will be assessed by measuring the number of falls during balance perturbation testing.


Secondary Outcome Measures :
  1. Change in objective and subjective measures of Balance [ Time Frame: Study weeks 2, 4 and 8 ]
    The effect of L-DOPS on assessments of balance by Movement Disorder Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 83 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject has voluntarily signed and dated an informed consent form (ICF), approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), and provided Health Insurance Portability and Accountability Act (HIPAA) (or other applicable privacy regulation) authorization prior to any participation in the study.
  2. Subject is male or female and is ≥ 30 and ≤ 83 years of age.
  3. Parkinson's diagnosis with history of falls or gait difficulty.
  4. Subject demonstrates neurogenic orthostatic hypotension (drop of 20 mm/Hg Systolic or 10 mm/Hg diastolic or both within 3 min of standing)
  5. Fell more than once in past year.
  6. Montreal Cognitive Assessment (MoCA) score ≥ 21.
  7. Stable dose of levodopa, dopamine agonist, amantadine, and/or monoamine oxidase B inhibitor, i.e. unchanged for 1 month.
  8. Subject is ambulatory and able to walk ≥ 10 meters with/without the use of an assistive device.

Exclusion Criteria:

  1. Subject has a clinical diagnosis of an atypical Parkinsonism
  2. Subject has a clinical diagnosis of PD that is suspicious to the investigator as being a possible case of atypical Parkinson's
  3. History of significant psychiatric illness such as schizophrenia or bipolar affective disorder or any other significant psychiatric illness that in the opinion of the investigator would interfere with participation in the study; history of major depressive disorder in the past year, or current major depressive episode
  4. Patients with systolic BP ≤70 mm/hg
  5. Subjects with a history of coronary artery disease or congestive heart failure
  6. Participation in another investigational drug or device study in during the 60 days prior to the Screening Visit
  7. Treatment with any anti-hypertensive medications
  8. Treatment with any anti-spasmodic medications
  9. Treatment with medications intended to elevate blood pressure
  10. Treatment with non-specific monoamine oxidase (MAO) inhibitors

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03567447


Contacts
Layout table for location contacts
Contact: Margaret McCauley 602-406-8134 Margaret.McCauley@dignityhealth.org
Contact: Pam Dewey 602-406-8252 pam.dewey@dignityhealth.org

Locations
Layout table for location information
United States, Arizona
Barrow Neurological Institute at St. Joseph's Hospital and Medical Center Recruiting
Phoenix, Arizona, United States, 85013
Contact: Margaret McCauley, RN    602-406-8134      
Sponsors and Collaborators
St. Joseph's Hospital and Medical Center, Phoenix
H. Lundbeck A/S
Arizona State University
Investigators
Layout table for investigator information
Principal Investigator: Abraham Lieberman, MD Barrow Neurological Insitute
Layout table for additonal information
Responsible Party: St. Joseph's Hospital and Medical Center, Phoenix
ClinicalTrials.gov Identifier: NCT03567447    
Other Study ID Numbers: 16-0200-80-04
First Posted: June 25, 2018    Key Record Dates
Last Update Posted: October 29, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by St. Joseph's Hospital and Medical Center, Phoenix:
Parkinsons Disease
PD
Patient Falls
Neurogenic Orthostatic Hypotension
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Hypotension, Orthostatic
Hypotension
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Synucleinopathies
Neurodegenerative Diseases
Vascular Diseases
Cardiovascular Diseases
Orthostatic Intolerance
Primary Dysautonomias
Autonomic Nervous System Diseases
Droxidopa
Antiparkinson Agents
Anti-Dyskinesia Agents